Alto Neuroscience Announces Positive Phase 1 Results for ALTO-101, a Novel PDE4 Inhibitor in Development for Schizophrenia
Alto Neuroscience Announces Initiation of Phase 2 Study of ALTO-203 in Patients with Major Depressive Disorder
Alto Neuroscience Reports Full Year 2023 Financial Results and Recent Business Highlights
Alto Neuroscience Appoints Maha Radhakrishnan, M.D., to Board of Directors
Alto Neuroscience to Participate in Upcoming Investor Conferences
Alto Neuroscience to Present at the TD Cowen 44th Annual Healthcare Conference
Alto Neuroscience Announces Closing of Upsized Initial Public Offering
In a second busy week of biotech IPOs, Alto Neuroscience and Fractyl Health will both be jumping onto the public markets this morning with their sights set on raking in more than $100 million each.
Alto Neuroscience Announces Pricing of Upsized Initial Public Offering
As Alto Neuroscience’s machine learning-derived, biomarker-based depression therapies accrue positive phase 2 data, the company is planning to join the growing trickle of biotechs aiming to IPO in early 2024.